more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$12.21 USD

-1.18 (-8.81%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $12.21 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

Top 25% (63 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Zacks News

Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC

by Zacks Equity Research Published on August 30,2022

Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.

pharmaceuticals

Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?

by Zacks Equity Research Published on August 30,2022

Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.

Down 21.7% in 4 Weeks, Here's Why Dynavax Technologies (DVAX) Looks Ripe for a Turnaround

by Zacks Equity Research Published on August 30,2022

The heavy selling pressure might have exhausted for Dynavax Technologies (DVAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

DVAXNegative Net Change

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

by Zacks Equity Research Published on August 29,2022

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

by Zacks Equity Research Published on August 29,2022

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

by Zacks Equity Research Published on August 26,2022

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

by Zacks Equity Research Published on August 25,2022

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

pharmaceuticals

Is Dynavax Technologies (DVAX) a Great Value Stock Right Now?

by Zacks Equity Research Published on August 25,2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVAXNegative Net Change

Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

by Zacks Equity Research Published on August 23,2022

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

pharmaceuticals

Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up

by Zacks Equity Research Published on August 23,2022

Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.

pharmaceuticals

Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval

by Zacks Equity Research Published on August 22,2022

Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

by Zacks Equity Research Published on August 18,2022

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt

by Zacks Equity Research Published on August 17,2022

Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.

pharmaceuticals

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

by Zacks Equity Research Published on August 16,2022

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research Published on August 16,2022

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research Published on August 12,2022

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

pharmaceuticals

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

by Zacks Equity Research Published on August 10,2022

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research Published on August 08,2022

Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 92%

by Zacks Equity Research Published on August 08,2022

The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

DVAXNegative Net Change